Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 5, 2002, Pages 383-388

  Harenberg, Job ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CERTOPARIN; D DIMER; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

AREA UNDER THE CURVE; BLEEDING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; THROMBOEMBOLISM;

EID: 0036326333     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200209000-00007     Document Type: Review

References (28)

1. A comparison of low-molecular-weight heparin administered in the hospital for proximal deep-vein thrombosis
2. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
3. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis
4. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin
5. Comparative human pharmacology of low molecular weight heparins
6. Low molecular weight heparins
7. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
8. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
9. Low molecular weight heparin therapy: Is monitoring needed?
10. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
11. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy
12. Association of changes in D-dimer and other coagulation markers with changes in Marder Score after treatment of acute venous thrombosis
13. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
14. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
15. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
16. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis
17. Fixed-dose body weight-independent subcutaneous LMW-heparin (LMWH) Certoparin is equally effective to adjusted-dose intravenous UF-heparin (UFH) for the initial treatment of proximal deep venous thrombosis (DVT)
18. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers
19. Does high-dose LMW-heparin accumulate over 9 days in patients with acute deep venous thrombosis
20. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives
21. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis
22. Roentgen diagnosis of venous thrombosis in the leg
23. Reduction in thrombus extension and clinical endpoints in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin
24. Reduced re-occurrence of venous thromboembolism over 6 months in patients with deep-vein thrombosis treated initially with subcutaneous body-weight independent low-molecular-weight heparin Certoparin
25. For the initial treatment of venous thromboembolism: Are all low-molecular-weight heparin compounds the same?
26. Heparin pharmacokinetics and pharmacodynamics
27. A 6-month venographic follow-up in 164 patients with acute deep vein thrombosis
28. D-Dimer levels in patients with long-term antecedents of deep venous thrombosis